Mesenchymal stem cell–gut microbiota interaction in the repair of inflammatory bowel disease: an enhanced therapeutic effect. Issue 1 (23rd December 2019)

• Record Type: Journal Article
• Authors: Ocansey, Dickson Kofi Wiredu; Wang, Li; Wang, Jingyan; Yan, Yongmin; Qian, Hui; Zhang, Xu; Xu, Wenrong; Mao, Fei
• Is Part Of: Clinical and translational medicine. Volume 8:Issue 1(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-12-23
• Subjects: Mesenchymal stem cell therapy -- Fecal microbiota transplant -- Inflammatory bowel disease -- MSC–gut bacteria interaction -- Combined therapy; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1186/s40169-019-0251-8
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: Background: Several investigations affirm that, patients with inflammatory bowel disease (IBD) exhibit dysbiosis characterized by restricted biodiversity and imbalanced bacterial composition intertwined with immune dysregulation. The interaction between stem cells and gut microbiota is a novel and highly promising field that could add up to a better understanding of the gut physiology, as well as therapeutic improvement towards diseases like IBD. Through direct contact or release of products and/or metabolites, gut bacteria regulate gut homeostasis, damage repair, regeneration and differentiation of stem cells. In the same way, mesenchymal stem cells (MSCs) produce similar effects including restoration of gut–microbiome composition. Body: We reviewed the anti‐inflammatory, antimicrobial, pathogenic bacterial clearance, proliferation and tissue remodeling effects of mesenchymal stem cells (MSCs) and fecal microbiota transplantation (FMT) as separate transplants in IBD, and the outcome of the interaction between MSCs and gut microbiota. Conclusion: The two therapies share several points of connection in therapeutics with enhanced functionalities in their interaction with each other. Focused investigations of MSC–gut bacteria interactions could lead to a novel discovery in therapeutics. We also anticipate an improved clinical remission rate in a combined FMT–MSC transplantation approach in IBD than the current single FMT or MSC approach.